OKYO Pharma (OKYO) Total Non-Current Liabilities (2023 - 2025)
OKYO Pharma (OKYO) posted quarterly Total Non-Current Liabilities of $8.0 million for Q3 2025, down 20.03% year-over-year from $10.0 million in Q3 2024, and down 12.79% quarter-over-quarter from $9.1 million in Q1 2025.
OKYO Pharma (OKYO) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
OKYO Pharma (OKYO) has reported Total Non-Current Liabilities for 3 consecutive years, with $8.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Total Non-Current Liabilities fell 20.03% year-over-year to $8.0 million; the TTM figure through Sep 2025 stood at $8.0 million (down 20.03% YoY), while the FY2025 annual figure was $9.1 million, up 24.65% from the prior year.
- Total Non-Current Liabilities retreated to $8.0 million in Q3 2025 per OKYO's latest filing, from $9.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $10.0 million in Q3 2024 and bottomed at $7.3 million in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $8.5 million across 3 years, with a median of $8.2 million in 2023.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 24.65% in 2025 and fell as far as 20.03% in 2025.
- OKYO Pharma's Total Non-Current Liabilities stood at $8.2 million in 2023, then gained by 21.09% to $10.0 million in 2024, then dropped by 20.03% to $8.0 million in 2025.
- Business Quant data shows OKYO's Total Non-Current Liabilities at $8.0 million in Q3 2025, $9.1 million in Q1 2025, and $10.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | OKYO Pharma | 1.52 Bn | 1.52 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.97 Mn |
| Mar 31, 2025 | 9.13 Mn |
| Sep 30, 2024 | 9.96 Mn |
| Mar 31, 2024 | 7.33 Mn |
| Sep 30, 2023 | 8.23 Mn |